**Sir,**

We would like to thank [@bib1]) for their constructive comment on our article. We acknowledge that the question raised is of crucial interest and, as the evaluation of infarct-like necrosis (ILN) was not planned in our analyses, we went back to our samples in order to investigate it.

We adopted the definition of ILN previously proposed ([@bib3]) and we found 24 (37%) out of 65 patients showing ILN, characterised by large confluent areas of eosinophilic cytoplasmic remnants, located centrally within a lesion and surrounded by a rim of fibrosis with foamy macrophages ([Figure 1](#fig1){ref-type="fig"}). Infarct-like necrosis was observed in 1 (5%) out of 28 patients in the control group, in 4 (27%) out of 18 in the chemotherapy group and in 19 (83%) out of 24 in the bevacizumab group (*P*\<0.0001). The 'bevacizumab-related effect\' previously described was also confirmed in our study (bevacizumab group *vs* chemotherapy group, *P*=0.0009; [Table 1](#tbl1){ref-type="table"}).

In our samples, patients showing a pathologic response according to the classification proposed by [@bib2] were more likely to present ILN in comparison to patients showing no pathologic response: ILN was present in 71% of patients showing tumour regression grade (TRG) 1-2-3 *vs* 29% of patients with TRG 4--5 (*P*=0.0008). These data strengthen the observation that ILN should be regarded as a particular feature of pathologic response induced by preoperative treatments.

Exploratory outcome analyses showed no differences in terms of progression-free survival according to the presence of ILN both among all treated patients (HR=0.59, 95% CI:0.25--1.36; *P*=0.21) and in the bevacizumab group (HR=0.42, 95% CI:0.06--1.77; *P*=0.19). Nevertheless, such analyses in our cohort are affected by the relatively small sample size.

In conclusion, we definitely agree with the proposal from [@bib1]) to include the evaluation of ILN in future studies assessing pathologic response of colorectal liver metastases to preoperative treatments.

![**Examples of usual necrosis (A) and infarct-like necrosis (B).**](bjc2013652f1){#fig1}

###### Frequency of infarct-like necrosis in colorectal liver metastases according to treatment

                    **Bevacizumab group,** ***N*****=24**   **Chemotherapy group,** ***N*****=18**
  ----------------- --------------------------------------- ----------------------------------------
  Presence of ILN   19 (83%)[a](#t1-fn2){ref-type="fn"}     4 (27%)[b](#t1-fn3){ref-type="fn"}
  Lack of ILN       4 (17%)[a](#t1-fn2){ref-type="fn"}      11 (73%)[b](#t1-fn3){ref-type="fn"}

Abbreviation: ILN=infarct-like necrosis.

One patient not evaluable.

Three patients not evaluable; *P*=0.0009.
